Phillips Financial Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$550K Sell
2,528
-446
-15% -$98.9K 0.04% 140
2025
Q4
$680K Sell
2,974
-338
-10% -$77K 0.04% 129
2025
Q3
$767K Buy
3,312
+488
+17% +$99.4K 0.05% 127
2025
Q2
$524K Sell
2,824
-128
-4% -$23.8K 0.04% 139
2025
Q1
$619K Buy
2,952
+117
+4% +$22.7K 0.05% 123
2024
Q4
$504K Sell
2,835
-114
-4% -$21K 0.04% 131
2024
Q3
$582K Sell
2,949
-576
-16% -$108K 0.05% 130
2024
Q2
$605K Buy
3,525
+120
+4% +$19.9K 0.05% 126
2024
Q1
$620K Buy
3,405
+157
+5% +$27.1K 0.05% 123
2023
Q4
$503K Buy
3,248
+652
+25% +$95.1K 0.04% 129
2023
Q3
$387K Buy
2,596
+96
+4% +$14.1K 0.04% 135
2023
Q2
$337K Sell
2,500
-29
-1% -$4.25K 0.03% 142
2023
Q1
$403K Sell
2,529
-68
-3% -$10.4K 0.04% 128
2022
Q4
$420K Buy
2,597
+181
+7% +$27.8K 0.04% 118
2022
Q3
$324K Buy
+2,416
New +$347K 0.04% 124
2022
Q2
Sell
-1,684
Closed -$274K 106
2022
Q1
$274K Buy
+1,684
New +$245K 0.03% 128

Other funds holding ABBV

Phillips Financial Management's ABBV Position: Q1 2026 in Review

Phillips Financial Management reduced its AbbVie (ABBV) stake by 15% in Q1 2026, selling an estimated $98.9K and leaving 2,528 shares worth $550K. The position accounts for 0.04% of the portfolio, ranked #140.

Phillips Financial Management first reported a position in ABBV in Q1 2022 and has held it in 16 quarters since. The position peaked at $767K in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Phillips Financial Management held 2,528 shares of AbbVie worth $550K as of Q1 2026.
  • Phillips Financial Management sold 446 AbbVie shares in Q1 2026, an estimated $98.9K.
  • AbbVie made up 0.04% of Phillips Financial Management's portfolio in Q1 2026, its #140 holding.
  • Phillips Financial Management first reported a position in AbbVie in Q1 2022 and has held it in 16 quarters since.
  • Phillips Financial Management's AbbVie position peaked at $767K in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Phillips Financial Management's 13F filing for Q1 2026, filed 16 Apr 2026.